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ScienceDirectYarrowia lipolytica is a safe and robust yeast that has a history
of industrial applications. Its physiological, metabolic and
genomic characteristics have made it a superior host for
metabolic engineering. The results of optimizing internal
pathways and introducing new pathways have demonstrated
that Y. lipolytica can be a platform cell factory for cost-effective
production of chemicals and fuels derived from fatty acids,
lipids and acetyl-CoA. Two products have been
commercialized from metabolically engineered Y. lipolytica
strains producing high amounts of omega-3 eicosapentaenoic
acid, and more products are on the way to be produced at
industrial scale. Here we review recent progress in metabolic
engineering of Y. lipolytica for production of biodiesel fuel,
functional fatty acids and carotenoids.
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Introduction
Metabolic engineering is a process of optimizing native
metabolic pathways and regulatory networks or assem-
bling heterologous metabolic pathways for production of
targeted molecules using molecular, genetic and combi-
natorial approaches. The purpose of the metabolic engi-
neering is to generate a cell factory that produces cost-
effective molecules at industrial scale (Figure 1). In order
to carry out a successful metabolic engineering project,
the following factors should be considered: first, use of a
safe and robust host organism with genetic and physio-
logical advantages for the target product; second, under-
standing of the metabolic pathways, co-factor balances,
and regulatory networks; third, selection of effective
enzymes and genetic elements; fourth, analysis of stoi-
chiometry and thermodynamics; fifth, availability of effi-
cient transformation technology; and sixth, approaches to
reduce potential toxic intermediates and products. Sincewww.sciencedirect.com its inception [1,2], microbial metabolic engineering has
mainly focused on traditional model organisms such as
Escherichia coli and Saccharomyces cerevisiae [3–5].
Metabolic engineering of E. coli has achieved commercial
production of 1,3-propanediol and 1,4-butanediol by
DuPont [6] and Genomatica [7], respectively. S. cerevisiae
has been metabolically engineered to produce artemisinic
acid [8] and amorpha-4,11-diene [9], precursors of the
antimalarial drug artemisinin commercially produced by
Amyris. To reach cost-effective production of a product,
host selection is very important. For example, it has been
demonstrated that S. cerevisiae is a better host than E. coli
for production of artemisinin precursors [10]. Both E. coli
and S. cerevisiae have been selected as favored hosts for
metabolic engineering largely due to the availability of
classical genetic approaches, and accessibility of modern
molecular biological tools for these two extensively stud-
ied model organisms.
After three decades of studies, Yarrowia lipolytica has
emerged as a preferred non-conventional yeast for meta-
bolic engineering, especially for the production of chemi-
cals derived from acetyl-CoA, fatty acids (FA) and lipids
[11–16]. Y. lipolytica is a hemiascomycetous yeast, with a
history of industrial applications. It has been used as a
model oleaginous organism for a wide range of studies
including lipid accumulation and degradation, peroxisome
biogenesis, dimorphism, and protein secretion pathways
[12–14]. Extensive analyses show that Y. lipolytica is a safe
organism for industrial applications [17]. Wild type (WT)
Y. lipolytica strains can use glucose, fructose, glycerol and
hydrophobic substrates as carbon sources; strain Po1g can
also use xylose and sugarcane bagasse hydrolysate [18]. In
addition, Y. lipolytica strains have been engineered to use
sucrose [19,20]. When both glucose and fructose are avail-
able, Y. lipolytica uses glucose first; over-expression of a
hexokinase can help Y. lipolytica to effectively use fructose
[21]. As an aerobic organism; Y. lipolytica has high flux
through the pentose phosphate pathway (PPP) that gen-
erates co-factor NADPH to support fatty acid (FA) biosyn-
thesis [22,23]. Most Y. lipolytica strains are haploid, but can
also exist in diploid form that is more tolerant to various
conditions [13,16]. The whole genome sequence of strain
CLIB122 [24] and a draft genome sequence of strain PO1f
[25] have been published. Suitable genetic tools and trans-
formation technologies have been developed [11,13,16,26].
In this review, we will focus on recent advances in meta-
bolic engineering of Y. lipolytica for production of chemicals
derived from acetyl-CoA, FA and lipids.Current Opinion in Biotechnology 2015, 36:65–72
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Metabolic engineering illustration. Metabolic engineering is a process to optimize an internal metabolic pathway and its regulatory networks or
assemble and coordinate a heterologous metabolic pathway within a cell for production of a target molecule using molecular, genetic and
combinatorial approaches.Metabolic engineering of lipid biosynthesis
and application for biodiesel production
Biodiesel is a mixture of FA esters [27,28] that is currently
produced from vegetable oil and animal fats. The global
production reached 180 Mt/year in 2012 [27]. Ideally,
biodiesel production should use renewable and sustain-
able substrates, and should not compete with the food and
feed supply. Microbial oils with similar FA composition
and energy value of plant oils are suitable for biodiesel
production. The FA composition of Y. lipolytica lipid is
similar to soybean oil, rich in C16 and C18 unsaturated
FAs [12,15,27]. Biodiesel produced from these FAs will
maintain liquid form under extreme cold conditions.
Significant progress has been achieved toward production
of cost-effective lipids from Y. lipolytica.
Some Y. lipolytica strains are oleaginous organisms that
can synthesize FA from glucose or other sugars and
accumulate lipids to more than 25% DCW [11,12]. More
than 90% of Yarrowia lipid is accumulated in triacylgly-
cerol (TAG) form from this de novo FA biosynthesis
pathway [12,13,15]. Y. lipolytica can also use an ex novo
process to accumulate intracellular lipids by incorporation
of exogenous FAs and lipids. Both the de novo and ex novo
lipid accumulation and the underlying mechanisms
(Figure 2) have begun to be elucidated. The de novo
FA synthesis starts from acetyl-CoA. When Y. lipolytica
cells sense nutritional limitation in their environment,
such as nitrogen starvation with excess of glucose in
controlled fermentation processes, citric acid is over-pro-
duced and pumped out from the mitochondria. Cytosolic
citric acid is converted to acetyl-CoA and oxaloacetate by
ATP-citrate lyase (ACL), an enzymatic activity which is
crucial for FA biosynthesis. The conversion of acetyl-CoACurrent Opinion in Biotechnology 2015, 36:65–72 to malonyl-CoA by carboxylase (ACC1) is the committing
step in FA biosynthesis. The synthesized C16 and C18
acyl-CoAs can be incorporated into lipids via the Ken-
nedy pathway; and can be stored in lipid bodies (LB) or
metabolized via the beta-oxidation pathway in peroxi-
somes. The required co-factor NADPH for FA biosyn-
thesis is derived mainly from the PPP. Up-regulation of
glucose-6-phosphate dehydrogenase and 6-phosphoglu-
conolactonase of the PPP can increase NADPH supply
[29]. Unlike some other oleaginous microorganisms, there
is no cytosolic malic enzyme (ME) in Y. lipolytica [30].
Over-expression of the mitochondrial form of ME was not
shown to affect FA biosynthesis [30]. Over-expression of
a heterologous pyruvate carboxylase (PYC) increased
lipid content more than 20%. When the engineered strain
over-expressed both PYC and ACL1, the lipid content
reached 45% DCW, which was about 50% increase over
the parent strain [31]. These results suggest that over-
expression of PYC, ACL and ACC1 ‘push’ the carbon flux
into FA biosynthesis pathway.
The regulatory network of lipid biosynthesis in Yarrowia
is starting to be elucidated. The sucrose non-fermenting 1
(Snf1) protein kinase is a key regulator in glucose signal
transduction in S. cerevisiae [32]; recent studies have
demonstrated that SNF1 is also a negative regulator of
de novo FA biosynthesis pathway, especially in the tran-
sition from growth to oleaginous phase in Y. lipolytica
(Figure 3). The snf1 null mutant constitutively synthe-
sized FA at high levels, resulting in a 2.6-fold increase of
lipid content over the control strain [33]. MIG1 is a
repressor in the SNF1 network. The mig1 defective
mutant produced lipids at 48.7% DCW, while the WT
strain produced lipids at 36% DCW [34]. The expressionwww.sciencedirect.com
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Overview of metabolic engineering of Y. lipolytica to produce molecules derived from fatty acid (FA), lipids or acetyl-coA. Cytosolic glucose enters
glycolysis and pentose phosphate pathways. Pyruvate enters mitochondria where it is converted into acetyl-CoA then used in TCA cycle. Excess
citrate is transported from the mitochondria into cytosol. ATP citrate lyase (ACL) converts the cytosolic citrate into acetyl-CoA that is converted
into malonyl-CoA by acetyl-CoA carboxylase (ACC), the first committing step of FA synthesis. After FA synthesis, triacylglycerol (TAG) is
synthesized in the endoplasmic reticulum (ER) via Kennedy pathway and then accumulated in lipid bodies (LB). Acyl-CoA is used for acylation of
glycerol-3-phosphate to form lysophosphatidic acid (LPA) that is further acylated to form phosphatidicacid (PA). PA is dephosphorylated to form
diacylglycerol (DAG), which is then acylated to produce TAG catalyzed by DAG acyltransferase (DGAT). TAG can also be synthesized by
phospholipid (PL):DAG acyltransferase (PDAT) using PL and DAG as substrates. Ex novo FA accumulation also uses Kennedy pathway. FA is
metabolized by b-oxidation pathway in peroxisome. Abbreviations: a-KG, alpha-ketoglutarate; DHAP, dihydroxyacetone phosphate; G3P,
glyceraldehyde3-phosphate; GPD1, glycerol-3-phosphate dehydrogenase; GUT2, glycerol-kinase; ME, malic enzyme; OAA, oxaloacetate; PEP,
phosphoenolpyruvate; Pex3 and Pex10, peroxisome biogenesis factor 3 and 10, respectively; Pox1 to Pox6, acyl-CoA oxidases 1–6, respectively;
TGL3 and TGL4, TAG lipase 3 and 4, respectively; PYC, pyruvatecarboxylase; TCA, tricarboxylic acid cycle. Yellow box: schematic diagram of
aerobic pathways for v-3 and v-6 FA biosynthesis. Abbreviations: C16E, EL1, C20E and D9E are C16/C18, C18, C20/C22, D-9 elongases,
respectively. D4D, D5D, D6D, D8D, D9D, D12D, D15D and D17D are D-4, D-5, D-6, D-8, D-9, D-12, D-15, and D-17 desaturases, respectively.
Light blue box: schematic diagram of carotenoid biosynthesis pathway. Abbreviations: IPP, isopentenyl diphosphate; DMAPP, dimethylallyl
diphosphate; GPP, geranyl pyrophosphate; FPP, farnesyl pyrophosphate; GGPP, geranylgeranyl pyrophosphate; HMG, HMG reductase; CrtE,
GGPP synthase; CrtB, phytoene synthase; CrtI, phytoene desaturase; CrtY, lycopene cyclase; CrtW, b-carotene ketolase; CrtZ, b-carotene
hydroxylase. Solid ovals: transporters. Light dash lines: possible route, not confirmed. Thin line: weak activity.of many lipid-related genes was changed in the snf1 and
mig1 mutants [33,34].
The committing step for TAG biosynthesis is catalyzed
by diacylglycerol (DAG) acyltransferase (DGAT). Y.www.sciencedirect.com lipolytica contains three classes of DGAT: DGAT1,
DGAT2, and a phospholipid:diacylglycerol acyltransfer-
ase (PDAT). Compared to the WT strain, the lipid
content reduced 64% or 87% in strains with dgat2 or
dagt1/dgat2/pdat genotype [35], respectively. A similarCurrent Opinion in Biotechnology 2015, 36:65–72
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Schematic presentation of Snf1 signal transduction pathway in Yarrowia. (a) When glucose is unlimited (red arrow up), Ssn6-Tup1 and Mig1
repressors repress the transcription of responsive genes. (b) When glucose is limited (red arrow down), Snf1 is activated and removes Mig1
repressor from promoters to de-repress glucose repressible genes that include those for alternative C-source utilization like beta-oxidation,
gluconeogenesis, and respiration (TCA). Y. lipolytica is an obligate aerobe, glucose repression is not as strict as in S. cerevisiae. Abbreviations:
Mig1, a zinc finger repressor; P, phosphate; RNAP, RNA polymerase; Sip4, a Zn(2)Cys(6) transcriptional activator; Snf1, SNF1 protein kinase;
Ssn6-Tup1, Ssn6-Tup1 repressor complex.effect of dgat2 was also observed in strain W29 [36]. When
the DGAT2 was over expressed in WT or pex10 (peroxi-
somal biogenesis factor 10) strains, the lipid content
reached 38% and 52% DCW [37], respectively. ACC1
over-expression in the WT strain resulted in about 2-fold
lipid increase over control. When the ACC1 and DGAT2
were simultaneously over-expressed, the lipid content
reached about 62% DCW. The overall lipid yield was
0.195 g/g glucose, which was about 61% of the theoretical
maximum yield of 0.32 g/g [38]. Over-expression of
DGAT2 in a strain with pex10/mfe1 (a peroxisomal hydro-
xyacyl coenzyme A dehydrogenase) resulted in lipid
production at 87% DCW [39]. These results suggest
that over-expression of DGAT2 builds a sink to ‘pull’ the
TAG biosynthesis.
Significant progress has been achieved in understanding
and engineering the de novo lipid biosynthesis in Y.
lipolytica. However it is still a challenge to produce
cost-effective biodiesel from this process if glucose is
used as the carbon source. Assuming a glucose price is
of $400/Mt, and an engineered strain produces lipids at
maximum yield 0.32 g/g, the glucose cost will be $1.25/kg
lipid. Therefore, there is great potential if Y. lipolytica can
use sugars from in vivo lignocellulose processes [40,41],
which will significantly reduce the sugar cost.
Yarrowia can also utilize an ex novo process to accumulate
lipids by incorporation of exogenous FAs and lipids
(Figure 2). Elimination of beta-oxidation by knockoutCurrent Opinion in Biotechnology 2015, 36:65–72 of POX genes encoding the acyl-CoA oxidases increased
lipid accumulation, and expression of POX2 in the Yar-
rowia mutant ( pox2/pox3/pox5) produced cells almost
entirely occupied by LB when grown on oleic acid
[42]. The ex novo lipid accumulation reached 80%
DCW when the glycerol 3-phosphate (G3P) pool was
increased by either GUT2 deletion or GPD1 over-expres-
sion in strains with eliminated b-oxidation [43,44]. The
mutation of FAT1, determining FA export from LB,
increased lipids 54% over control strain [45]. Additional-
ly, the capacity for lipid accumulation was doubled by
inactivation of either one or both TAG lipases localized in
LB [46]. The ex novo lipid accumulation by Y. lipolytica
has the potential to produce cost-effective biodiesel if
appropriate agricultural and industrial oil wastes can be
used as substrates.
Metabolic engineering of Y. lipolytica to
produce functional fatty acids
Although the FA composition is similar to soybean oil
[13,37], the only polyunsaturated FA in Yarrowia lipid
is linoleic acid (LA, C18:2n-6). The v-3 FAs a-linolenic acid
(ALA, C18:3n-3), stearidonic acid (STA, C18:4n-3), eicosa-
pentaenoic acid (EPA, C20:4n-3), docosapentaenoic acid
(DPA, C22:5n-3), docosahexaenoic acid (DHA, C22:6n-3);
and the v-6 FAs g-linolenic acid (GLA, C18:3n-6), dihomo-
g-linolenic acid (DGLA, C20:3n-6) and arachidonic acid
(ARA, C20:4n-6) are all commercially relevant products. Y.
lipolytica has been developed as a platform cell factory to
produce these v-3 and v-6 FAs [11,37,47].www.sciencedirect.com
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ase (D6D) in Y. lipolytica resulted in GLA accumulation as
over 25% total lipids [48,49]. Increasing copy number of
D12D and D6D, and the over-expression of C16/C18
elongase (C16E) [50] in a pex3 mutant significantly in-
creased GLA production to reach 60% total lipids [Zhu
et al., unpublished data]. Similar strategies were
employed to generate Yarrowia strains to produce DGLA
and ARA to reach 42% and 35% total lipids, respectively
[37].
Yarrowia strains have been generated to produce EPA as
the first commercial product. EPA is a key component in
fish oil with known importance in human nutrition. A first
generation strain Y4305 containing 30 copies of nine
different heterologous genes was generated to produce
EPA at 56.6% total lipids and about 15% DCW [37].
Additional strains [51] were later developed by combi-
nation of several strategies. First, an efficient EPA bio-
synthetic pathway was built using strong promoters,
codon-optimized heterologous genes, and multiple gene
copies for each step. Second, the carbon flux was pushed
toward the EPA biosynthesis pathway by over-expression
of C16E [50] and D12D [52], and was pulled for EPA
biosynthesis by using multiple copies of D17-desaturase
genes [53]. Third, b-oxidation was eliminated by targeted
deletion of peroxin genes [37,54]. Fourth, EPA trans-
portation was controlled by fine regulation of different
acyltransferases [11,51]. The new commercial strain
Z5567 containing 41 copies of 19 different genes pro-
duced EPA at 50% total lipids and 25% DCW. Two
commercial products have been developed based on
EPA production strains. The purified EPA lipids have
been used to develop NewharvestTM EPA oil, for a
human nutritional supplement. The high-EPA biomass
has been used to raise Verlasso1, a sustainably farmed
salmon.
The feasibility of engineered Y. lipolytica to produce
DHA has also been demonstrated [55]. On the basis of
strain Y4305, a DHA strain was constructed by over-
expression of heterologous genes encoding for D4-desa-
turase (D4D) and C20 elongase (C20E), or a multizyme
having both D4D and C20E [56]. The DHA lipid con-
tains about 5% DHA, 13.5% DPA and 26.5% EPA, which
is similar to the seal oil [57] that contains high amounts of
beneficial v-3 DPA [58]. These studies have demonstrat-
ed that Y. lipolytica is a good host for metabolic engineer-
ing for production of v-3 and v-6 FAs. Strains can be
developed to produce cost-effective products with de-
sired FA compositions for specific applications.
Metabolic engineering of Y. lipolytica to
produce carotenoids
Carotenoids such as lycopene, b-carotene, canthaxanthin,
and astaxanthin are yellow to red-colored pigments; they
are antioxidants with health benefits for humans andwww.sciencedirect.com animals. The global market is expected to reach $1.4
billion in 2018 [59,60]. Currently, some carotenoids are
chemically synthesized, while others are sourced from
natural organisms. Metabolic engineering has the poten-
tial to produce these molecules more cost-effectively than
current methods. Large efforts have been focused on
using E. coli and S. cerevisiae as production hosts, and
have been well reviewed [59,60]. In this section, we will
review the progress toward production of carotenoids in
metabolically engineered Y. lipolytica.
Carotenoids (Figure 2) are biosynthesized from two C5
precursors, isopentenyl diphosphate (IPP) and dimethy-
lallyl diphosphate (DMAPP). As in other yeast, Y. lipo-
lytica has the mevalonate pathway to produce IPP and
DMAPP from acetyl-CoA. The geranyl pyrophosphate
synthase converts IPP and DMAPP into geranyl pyro-
phosphate (GPP; C10), which is subsequently converted
to farnesyl pyrophosphate (FPP; C15) and geranylgeranyl
pyrophosphate (GGPP; C20). HMG reductase (HMG) is
a rate-limiting step in the mevalonate pathway. If engi-
neered correctly, the high acetyl-CoA flux in Y. lipolytica
should produce more IPP and DMAPP, and then GGPP
for carotenoid biosynthesis. Both DuPont and Microbia
have separately selected Y. lipolytica as host for production
of carotenoids [61,62].
Simultaneous over-expression of codon-optimized CrtE,
CrtB, and CrtI in an EPA-producing strain accumulated
lycopene to 2 mg/g DCW in flask assays [61,63]. When
the codon-optimized CrtE, CrtB, CrtI, and HMG were
over-expressed in a mutant ( pox1–pox6 and gut2), the
engineered strain produced lycopene at 16 mg/g DCW
in fed-batch cultures [64]. The increased LBs of this
mutant provided a sink for lycopene storage. As demon-
strated in other systems, over-expression of a truncated
HMG may further increase the lycopene production [65].
Co-expression of codon-optimized CrtE, CrtB, CrtI and
CrtY in an EPA-producing strain accumulated b-carotene
to 5.7 mg/g DCW, and the b-carotene was about 64% total
carotenoids [61]. Microbia has also engineered Yarrowia
to produce b-carotene [62]. Their safety profile studies
showed that the b-carotene produced by Y. lipolytica is the
same as other commercial products [66]. The feasibility of
engineering Y. lipolytica to produce canthaxanthin and
astaxanthin has also been demonstrated [61]. Additional
research beyond what has been published would be
necessary to increase the production rate, titer, and yield
of these products to reach cost-effective commercial
production.
Perspectives
Metabolic engineering of Y. lipolytica provides a unique
platform for producing chemicals and fuels derived from
acetyl-CoA, FA, and lipids. Y. lipolytica has now been
metabolically engineered to produce omega-3 and ome-
ga-6 FAs, carotenoids and biodiesel. It is an attractiveCurrent Opinion in Biotechnology 2015, 36:65–72
70 Pathway engineeringplatform for robust, sustainable fermentation manufactur-
ing for a wide range of products. However, metabolic
engineering of Y. lipolytica is still in its infancy, and there
are a number of challenges to commercial success. Selec-
tion of the target molecule is very important for cost-
effective production. The following criteria need to be
considered. Does Y. lipolytica have physiological and
genetic advantages for the selected molecule? What is
the value of the product? Is there an existing chemical
route, and if so, what are the economic targets to be met to
make a biological route competitive? Products with high
value and pathways that produce a battery of useful
molecules will have obvious advantages. For lower value,
higher volume products, three major challenges must be
overcome.
First, the metabolic engineering research to build a
production strain with optimal production rate, titer
and yield must be accomplished much faster and cheaper
than has been possible till date. More basic research is
needed to understand the physiology, biochemistry and
genetics of WT and engineered strains. Improved pre-
dictive modeling, combinatorial and automated gene
cloning, and metabolic flux analysis will speed up the
strain construction process. New technologies such as
site-specific gene editing methods and sensor-based high
throughput assays will be important to reduce time and
cost of metabolic engineering.
Second, substrate cost must be substantially reduced.
Since our knowledge is still limited, reaching theoretical
yield is a big challenge for most products. Increased
understanding of the physiology and biochemistry of
WT and engineered strains will be valuable in optimizing
yield. However, the cost of conventional substrates such
as glucose, sucrose, or glycerol will remain a barrier to
commercial success for lower value products. Alternative
lower cost substrates, such as biomass-derived sugars, or
low cost agricultural oils, must be utilized. Each of these
will present different problems for Yarrowia physiology
and for bioprocess development.
Third, capital investment for manufacturing assets must
be reduced. Creative innovation in fermentation engi-
neering and downstream processing will be required for
industrial applications of biological manufacturing with
using Yarrowia and (or other microorganisms) to become
widely used. For example, a continuous fermentation
process which performs with the same yield and titer
as the fed batch fermentation will significantly increase
the volumetric productivity of the process, and thereby
decrease the capital investment in both fermentation and
downstream process equipment.
Y. lipolytica shows considerable promise to meet the chal-
lenges in each of these three areas. With further advances
in our knowledge and tools, metabolic engineering ofCurrent Opinion in Biotechnology 2015, 36:65–72 Y. lipolytica will play a more important role for industrial
applications, and will help to provide more sustainable and
renewable products to society in the future.
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